Oncology
Metastatic Breast Cancer
Conference Reporter® Podcast: Circulating Tumor DNA, ESR1 Mutations, and Endocrine Combinations in HR+/HER2- Metastatic Breast Cancer
Circulating tumor DNA testing can identify tumor-derived mutations and support biomarker-based treatment assignment in HR+/HER2- metastatic breast cancer. Today’s podcast features an interview with Komal Jhaveri, MD, FACP, FASCO, highlighting data from the 2026 ASCO Annual Meeting on ESR1 mutations, oral SERDs, and endocrine-based combinations after CDK4/6 inhibitor therapy.
Following this presentation, featured expert Komal Jhaveri, MD, FACP, FASCO, was interviewed by Conference Reporter Associate Editor-in-Chief Christopher Ontiveros, PhD. Clinical perspectives from Dr Jhaveri on these findings are presented here.
Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30(19):4299-4309. doi:10.1158/1078-0432.CCR-24-1073
Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246-3256. Published correction appears in J Clin Oncol. 2023;41(23):3962.
Campone M, De Laurentiis M, Jhaveri K, et al; VERITAC-2 Study Group. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393(6):556-568. doi:10.1056/NEJMoa2505725
Jhaveri KL, Neven P, Casalnuovo ML, et al; EMBER-3 Study Group. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392(12):1189-1202. doi:10.1056/NEJMoa2410858
Jhaveri KL, Rugo HS, Tolaney SM, et al. Post-progression treatment (tx) analyses of evERA breast cancer (BC): a phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2- aBC) previously treated with a CDK4/6 inhibitor (i) [abstract 1016] [session: Breast cancer—metastatic]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Martín M, Lim E, Chavez-MacGregor M, et al; acelERA Breast Cancer Study Investigators. Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. J Clin Oncol. 2024;42(18):2149-2160. doi:10.1200/JCO.23.01500
Sahin TK, Aksoy S, Guven DC. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors. Expert Rev Anticancer Ther. 2025;25(5):471-484. doi:10.1080/14737140.2025.2479604
Yarunin A, Ahlgren H, Chaki M, Morrow C, Li X, Longshore J. ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer. Expert Rev Mol Diagn. 2025;25(12):903-914. doi:10.1080/14737159.2025.2576021
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
Explore More in Metastatic Breast Cancer
Metastatic Breast Cancer
Prediction of Response and Resistance to Antibody-Drug Conjugate Therapy for HR+/HER2- Metastatic Breast Cancer
Metastatic Breast Cancer
